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IT is well known that whereas folic acid antagonists may induce temporary
remissions in various forms ofmalignant disease, apparently permanent remissions
can be obtained in a high proportion of patients with choriocarcinoma. Broquist
(1956) and Hiatt, Goldstein and Tabor (1958) observed that patients receiving a
folic acid antagonist for leukaemia showed an abnormal excretion of formimino-
glutamic acid in patients with various forms of cancer before any form oftherapy.
It has also been reported that patients with cancer, including the leukaemias,
frequently have low serum folate values (Rao et al., 1965) but others have sug-
gested that this correlated with nutritional status (Hellman, Iannotti and Bertino,
1964) and that the serum folate was not more depressed than in comparable
hospital patients with non-malignant disease (Spector, Hutter and Fedorko, 1966).
In the present paper we report the serum folate and formiminoglutamic acid
excretion of patients with trophoblastic tumours. Changes in formiminoglu-
tamic acid (FIGLU) excretion during treatment with the folic acid antagonist
methotrexate have also been studied in some of these patients.
MATERIALS AND METHODS
FIGLU excretion test.-The patients were given 15 g. of L-histidine mono-
chloride orally, during a half hr. period, and the urine was collected for 8 hr.
starting 1 hr. after commencing to take the histidine. The collecting bottle
contained 10 ml. N HCI as a preservative and was stored at -20° C. until assayed.
E.stirnation ofFIGLU.-FIGLU was determined by modification ofthe spectro-
photometric enzyme method of Chanarin and Bennett (1962).
As some of the urine specimens contained methotrexate, it was necessary to
inhibit all the folic reductase present at the end ofpre-incubation. Excess metho-
trexate (5 ,tg.) was added to all the incubation tubes before the addition of
standards and urine samples.
Serum folate.-Serum folate was estimated by the L. casei method of Waters
et al. (1961) and Waters and Mollin (1963) with the following modifications. The
serum was diluted 1: 50 with the ascorbate phosphate buffer before autoclaving,
and the time of incubation of the inoculated tubes was increased to 40 hr.
Chorionic gonadotrophin.-Chorionic gonadotrophin (HCG) was measured in
24 hr. urine samples by the method of Wilde, Orr and Bagshawe (1967).
Subjects and treatment re'gimes
The patients studied and the analyses performed are indicated in Table I.
The treatment regimes received by patients studied with serial-estimations of
FIGLU excretion are shown in Table II.SERUM FOLATE AND FIGLU EXCRETION
TABLE I.-Analysis ofPatients According to Disease Category and Studies Performed
Serum folate Initial FIGLU Serial FIGLU
Choriocarcinoma
Invasive mole .
Invasive trophoblastic neoplasm .
(histological type unknown)
Malignant teratoma trophoblastic
14
1
14
5
6
1
8
1
4
0
6
2
TABLE II.-Treatment Re'gimesfor Patients Studied with Serial FIGLU Estimations
R6gime No. 1. . Methotrexate 25-30 mg. daily and 6-mercaptopurine 200-400 mg. in 5
(3 cases) divided doses daily by mouth for 3-5 days followed by rest periods of
7-10 days.
Regirre No. 2.
(3 cases)
Regime No. 3.
(6 cases)
. Methotrexate 5 mg. daily by continuous intra-arterial infusion for 5-7
days followed by a 7-9 days rest period.
Methotrexate 25 mg. daily by continuous intra-arterial infusion for 7 days
followed by a 7 days rest period. Folinic acid (leucovorin) 6 mg.
every 12 hr., intramuscularly, throughout the infusion period.
RESULTS
The results are summarised in Table III. The initial FIGLU excretion was
above normal (>20 mg./8 hr.) in 12 of the 16 subjects studied. The serum
folate values on admission to Fulham Hospital were plotted against the initial
excretion rates of HCG (Fig. 1) and against the interval in weeks since the ante-
EXCRETION OF HCG i.u./24 hours
FIG. 1.-Serum folate value and chorionic gonadotrophin (HCG) excreted in patients with tropho-
blastic tumours before treatment.
Regression lines
log x = 6-2415 -0-2462 y
y = 10 1064 - 107691ogx
Correlation:
r = 0-51
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TABLEIJJI.-Summary of Result
Interval Duration
Serum Urine since of
Hb. FIGLUJ folate HOG pregnancy treatment Diagno-
Case No. Age g./100 ml. mg./8 hr. myig./ml. i.u./day Parity (weeks) (weeks) sis
75 22 10.9 - 8-5 20,000 0 23 11 ITN
76 18 10.99 8-5 155,000 1 26 48 cc
80 2312- 4 - 6* 2 58,000 1 43 8 cc
84 27 13*2 136 - 790 0 87 9 ITN
86 40 10.5 6- 5 3200 4 14 42 cc
87 17 14*7 - 7-25 6000 0 36 c cC
89 20 11*4 - 245 1,200,000 0 46 43 ITN
91 301l- 8 - 45 700,000 0 24 7 cc
94 17 89 - 4 45 80,000 0 10
100 26 12-4 5- 75 50,000 0 16 18 ITN
101 32 14*1 - 3-75 47,000 4 34 cc
104 22 102 2 30 23,000 0 22 7 ITN
110 18 12-9 12966-25 72,000 0 12 16 ITN
1 11 27 108 8 30 135,000 0 89 78 cc
115 38 12- 2 555 4 - 7 224,000 2 19 5 12 ITN
116 27 12-7 - 4 5 53,000 1 4- 5 14 ITN
120 25 12-9 50 12,000,000 - - - NGCC
129 25 9*4 386 263,000 4 13 33 cc
131 40 13-0 5-0 1000 3 16 - CC
132 21 10-4 38 7 0 512,000 0 5 15 ITN
133 31 94 - 30 350,000 2 101 23 C c
136 26 9-2 175 2-5 1,200,000 - 20 NGCC
137 27 13-4 45 6-0 32,000 1 41 14 ITN
138 21 10-2 295 5-25 855,000 0 7 44 C c
139 18 10-4 15 7*5 6500 0 6-5 13 ITN
141 31 11-6 40 4-8 55,000 0 6 25 IM
143 30 12-2 76 2-3 312,000 1 117 26 Cc
149 40 7-8 1155 2-25 2,000,000 2 103 31 Cc
150 27 80 2-7 5,000,000 - NGCC
153 31 13-4 10 5- 5 18,000 1 23 15 ITN
156 30 10-5 64 150,000 3 16 25 CC
157 22 10-9 73 2-9 145,000 0 56 15 c c
159 28 11-7 19 5-5 30,000 0 11 11 ITN
161 27 11-5 - 1-5 1,800,000 1 65 18 ITN
162 31 11-7 2-2 106,000 21 NGCC
163 20 6-8 - 2-3 450,000 - 10 NGCC
165 24 11-5 4-0 600,000 4 10 7 Cc
Normal values
Abbreviations:
<2-0 >5-0 <100
CC = choriocarcinoma (post gestational)
IM = invasive mole
ITN = invasive trophoblastic neoplasia
NGCC = non-gestational choriocarcinoma
cedent pregnancy (Fig. 2). There was significant correlation between these
factors but the correlation was not close. Before treatment, serum folate was
below 5m,tg./ml. in 19 of 34 subjects studied.
Theresults ofserialFIGLUdeterminations onpatientsundergoing treatment
are shown in Fig. 3. With treatment regime No. 1,FIGLU excretion remained
high throughout the period ofstudy (Fig. 3a). Similarly, 2 of 3 patients who
received small amounts ofmethotrexate alone by continuous infusion also had
persistently high FIGLU excretion (Fig. 3b). The other subject in this group
showed low FIGLU excretion throughout. The patients who received folinic
acid in conjunction with methotrexate (Fig. 3c) either had low FIGLU values
throughout or, whereelevated initially, FIGLU excretion tended to fall during
treatment towards normal.
34SERUM FOLATE AND FIGLU EXCRETION
Two patients (Cases 136 and 138) received actinomycin-D (0.5 mg./day for
2-7 days) between courses of methotrexate. In neither instance was there any
gross change in FIGLU excretion although when methotrexate therapy was
resumed one of them (Case 138) showed a sharp rise in FIGLU excretion.
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INTERVAL IN WEEKS BETWEEN END OF ANTECEDENT PREGNANCY AND INVESTIGATI
FIG. 2.-Initial serum folate value plotted against the interval in weeks since the antecedent
pregnancy.
Regremion line8:
log x = 1-9112 -0-1117 y
y = 8-222 -2409 log x
Correlation:
r = 0-52
DISCUSSION
More than half our patients with trophoblastic tumours had subnormal serum
folate values before treatment. Those with extensive disease tended to have lower
values and this is reflected in an inverse relationship with the patient's gonado-
trophin excretion. The amount of gonadotrophin excreted provides an index
of the amount of viable tumour tissue so that it may be inferred that the more
extensive the disease the greater the probability that the serum folate is low.
Similarly there is a tendency for low serum folate levels to be found with increasing
time between the end of pregnancy and the time of diagnosis. Since the extent
ofdisease islikely to be influenced by its duration the associationisnotunexpected.
It is clear that the correlation between serum folate and extent of disease as
judged by HCG excretion is not a close one. There was no obvious correlation
between serum folate values and parity in these subjects.
The excretion offormiminoglutamic acid following a histidine load reflects the
availability offolate co-enzymes and the excretion ofthis metabolite might there-
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fore be expected to relate to serum folate values, but in the present data such a
relationship is dubious.
During treatment with methotrexate, a folic acid antagnoist, the pattern of
change in FIGLU excretion seems to be largely determined by the therapeutic
regime but since the 3 treatment groups were not similarly constituted with
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FIG. 3a.-Urinary formiminoglutamic acidexcretion in 3 patients during treatment with methotrexate
and 6-mercaptopurine.
(Regime No. 1.) 1 Methotrexate and 6-mercaptopurine
E1 Actinomycin-D.
respect to the type and extent of trophoblastic disease, this is not conclusive.
The group which received methotrexate by continuous intra-arterial infusion,
together with intermittent injections of folinic acid (leucovorin), either had
normal values for FIGLU throughout or they showed progressively falling values.
In this group the folinic acid evidently permitted histidine to be metabolised by
normal pathways and it is notable that although this therapeutic r6gime is
generally accompanied by little toxicity and wider safety margins, it is not less
efficient therapeutically against choriocarcinoma than r6gimes which cause more
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stomatitis and marrow depression. In the other 2 treatment groups FIGLU
excretion generally increased during treatment.
The results do not suggest that patients with trophoblastic tumours have a
gross disturbance of folate metabolism. The low serum folate values and ab-
normal FIGLU excretion would seem to reflect depleted reserves of folic acid but
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FIG. 3b.-Urinary formiminoglutamic acid excretion in 3 patientsduring treatment withmethotrexate
by continuous infusion.
(Regime No. 2.) m Methotrexate
V less than 10 mg. FIGLU in 8 hours.
the values do not differ significantly from those reported in patients with other
forms of malignant disease.
SUMMARY
A study of serum folate activity in patients with trophoblastic tumours
indicates that many of them have abnormally low values and that this shows a
relationship to the extent and duration of the disease. Serum folate activity is
not more profoundly depressed in these patients than has been reported in patients
with other forms of malignant disease.
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The excretion of FIGLU after histidine loading changed during treatment but
appeared to be determined by the nature ofthe therapeutic r6gime. A treatment
regime in which folinic acid was used in conjunction with the folic acid antagonist
resulted in high FIGLU excretion falling to low values without any impairment
of therapeutic efficiency.
This work was carried out with the aid of a grant from the British Empire
Cancer Campaign for Research.
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